首页> 外文期刊>中华医学杂志(英文版) >Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease
【24h】

Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease

机译:肺微生物组在慢性阻塞性肺疾病发病机理中的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:The development of culture-independent techniques for microbiological analysis shows that bronchial tree is not sterile in either healthy or chronic obstructive pulmonary disease (COPD) individuals.With the advance of sequencing technologies,lung microbiome has become a new frontier for pulmonary disease research,and such advance has led to better understanding of the lung microbiome in COPD.This review aimed to summarize the recent advances in lung microbiome,its relationships with COPD,and the possible mechanisms that microbiome contributed to COPD pathogenesis.Data Sources:Literature search was conducted using PubMed to collect all available studies concerning lung microbiome in COPD.The search terms were "microbiome" and "chronic obstructive pulmonary disease",or "microbiome" and "lung/pulmonary".Study Selection:The papers in English about lung microbiome or lung microbiome in COPD were selected,and the type of articles was not limited.Results:The lung is a complex microbial ecosystem;the microbiome in lung is a collection of viable and nonviable microbiota (bacteria,viruses,and fungi) residing in the bronchial tree and parenchymal tissues,which is important for health.The following types of respiratory samples are often used to detect the lung microbiome:sputum,bronchial aspirate,bronchoalveolar lavage,and bronchial mucosa.Disordered bacterial microbiome is participated in pathogenesis of COPD;there are also dynamic changes in microbiota during COPD exacerbations.Lung microbiome may contribute to the pathogenesis of COPD by manipulating inflammatory and/or immune process.Conclusions:Normal lung microbiome could be useful for prophylactic or therapeutic management in COPD,and the changes of lung microbiome could also serve as biomarkers for the evaluation of COPD.
机译:目的:独立于微生物学分析技术的发展表明,无论健康还是慢性阻塞性肺疾病(COPD)个体,支气管树都不是无菌的。随着测序技术的发展,肺微生物组已成为肺疾病研究的新领域。这项综述旨在总结肺微生物组的最新进展,其与COPD的关系以及微生物组在COPD发病机理中的可能作用机理。数据来源:文献检索使用PubMed进行研究以收集关于COPD中所有与肺微生物组有关的研究。搜索词为“微生物组”和“慢性阻塞性肺疾病”,或“微生物组”和“肺/肺”。研究选择:英文中有关肺微生物组的论文结果:肺是一种复杂的微生物。肺生态系统;肺中的微生物组是存在于支气管树和实质组织中的存活和不存活的微生物群(细菌,病毒和真菌)的集合,这对健康很重要。以下类型的呼​​吸道样本常用于检测肺微生物组:痰,支气管抽吸液,支气管肺泡灌洗液和支气管粘膜。细菌性微生物组参与了COPD的发病机制; COPD恶化期间微生物群也有动态变化。结论:正常的肺微生物组可用于COPD的预防或治疗管理,肺微生物组的变化也可作为评估COPD的生物标志物。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2017年第17期|2107-2111|共5页
  • 作者单位

    Department of Pulmonary and Critical Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100069, China;

    Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York 10001, USA;

    Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China;

    Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号